Skip to main content
WeLoveTrump.com may receive compensation from affiliate partners for some links on the site. Read our full Disclosure here.

CDC Allows the J&J COVID-19 Vaccine to Resume Despite Blood Clot Risks


564 views

It’s business as usual for Big Pharma.

After a brief stoppage of the J&J COVID-19 jab, an independent advisory panel for the CDC voted for it to resume on the FDA’s emergency use authorization.

So, the drug is still not FDA approved and there are known life-threatening risk factors.

No thanks, I’ll pass on that experimental cocktail.

Here’s more:

Warning label or not, I’d never inject that experimental drug into any part of my body.

There are others who aren’t too thrilled about the J&J vaccine either.

Another reason to not trust these experimental injections is the financial stake Big Pharma shills have.

Billions of dollars are at stake for them, so you know they want the vaccines out there at any cost.

It doesn’t matter what type of risk factors are present.

Life Site News reported:

An independent advisory panel for the Centers for Disease Control and Prevention (CDC) voted Friday 10 – 4 to recommend the continued use of the Johnson & Johnson (J&J) vaccine after the single-dose shot was paused over blood clotting concerns. The panel did not recommend adding any extra warning about the risk of rare blood clotting disorders.

The recommendation by the CDC’s Advisory Committee on Immunization Practices (ACIP) has to be approved by the CDC and the U.S. Food and Drug Administration (FDA) before becoming official government policy.

The ACIP said the link between blood clots and J&J’s COVID vaccine was “plausible,” but concluded the vaccine’s benefits still outweigh the risks and recommended the vaccine for persons 18 years of age and older in the U.S. under the FDA’s Emergency Use Authorization (EUA).

“This is a serious adverse event,” said Dr. Grace Lee, a pediatrician at the Lucile Packard Children’s Hospital and Stanford University School of Medicine in Stanford, California. “We need to continue to ensure that awareness is raised. But I also think that we have to come out with a clear recommendation,” she said.

GET THE TRUTH: DailyTruthReport.com

Dr. Pablo Sanchez, a pediatrician at The Ohio State University’s Nationwide Children’s Hospital in Columbus and one of the four “no” votes, said he supported returning the vaccine to the market, but felt it was important to add a warning. “We have to have stronger language to ensure people are (fully informed),” he said.

According to The Wall Street Journal, J&J was willing to add language to the vaccine’s label warning about the blood clot risk at the FDA’s request, J&J Chief Medical Officer Dr. Joanne Waldstreicher told members of the vaccine committee.

Waldstreicher said resumption of vaccinations with J&J’s shot would likely prevent many more deaths and hospitalizations from COVID than the number of rare blood clot cases that may occur in people receiving the vaccine.

“We believe the J&J COVID vaccine is central to the effort to end the pandemic,” Waldstreicher said.

According to The Washington Post, the CDC’s advisory panel found 15 women who were diagnosed with rare blood clots, including three deaths, seven who remain hospitalized and five recovering at home, according to a slide presentation shared during today’s meeting.

Only two of the women were older than 50, with the risk highest in women ages 30-39, according to theACIP. The findings appear to confirm the suspicion that younger women are more vulnerable to developing blood clots.



We Love Trump
Thanks for sharing!
Send this to a friend